BRAF-induced tumorigenesis is IKKα-dependent but NF-κB–independent
- 21 April 2015
- journal article
- research article
- Published by American Association for the Advancement of Science (AAAS) in Science Signaling
- Vol. 8 (373) , ra38
Abstract
KRAS mutations contribute to cell proliferation and survival in numerous cancers, including colorectal cancers (CRC). One pathway through which mutant KRAS acts is an inflammatory pathway that involves the kinase IKK and activates the transcription factor NF-κB. BRAF, a kinase that is downstream of KRAS, is mutated in a subset of CRC and is predictive of poor prognosis and therapeutic resistance. We found that, in contrast to mutant KRAS, mutant BRAF (BRAFV600E) did not trigger NF-κB activation but instead triggered the phosphorylation of a proteolytic fragment of IKKα (p45-IKKα) in CRC cells. BRAFV600E CRC cells had a high abundance of phosphorylated p45-IKKα, which was decreased by a RAF inhibitor. However, the abundance and DNA binding of NF-κB in these cells were unaffected by the RAF inhibitor, and expression of BRAFV600E in human embryonic kidney–293T cells did not activate an NF-κB reporter. Moreover, BRAF-induced transformation of NIH-3T3 cells and BRAF-dependent transcription required phosphorylation of p45-IKKα. The kinase TAK1, which was associated with the endosomal compartment, phosphorylated p45-IKKα. Inhibition of endosomal vacuolar adenosine triphosphatase (V-ATPase) with chloroquine or bafilomycin A1 blocked p45-IKKα phosphorylation and induced apoptosis in BRAF-mutant CRC cells independent of autophagy. Treating mice with V-ATPase inhibitors reduced the growth and metastasis of BRAFV600E xenograft tumors in the cecum of mice.Keywords
Funding Information
- Instituto de Salud Carlos III-FEDER (PI13/00448)
- AGAUR (SGR23)
- RTICCS/FEDER (RD12/0036/0054, RD09/0076/00036)
This publication has 40 references indexed in Scilit:
- Panitumumab–FOLFOX4 Treatment and RAS Mutations in Colorectal CancerNew England Journal of Medicine, 2013
- RAF Inhibitors Activate the MAPK Pathway by Relieving Inhibitory AutophosphorylationCancer Cell, 2013
- Tumour micro-environment elicits innate resistance to RAF inhibitors through HGF secretionNature, 2012
- Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trialThe Lancet, 2012
- Survival in BRAF V600–Mutant Advanced Melanoma Treated with VemurafenibNew England Journal of Medicine, 2012
- RAF inhibitors transactivate RAF dimers and ERK signalling in cells with wild-type BRAFNature, 2010
- RAF inhibitors prime wild-type RAF to activate the MAPK pathway and enhance growthNature, 2010
- Kinase-Dead BRAF and Oncogenic RAS Cooperate to Drive Tumor Progression through CRAFCell, 2010
- Implications for KRAS status and EGFR-targeted therapies in metastatic CRCNature Reviews Clinical Oncology, 2009
- K-rasMutations and Benefit from Cetuximab in Advanced Colorectal CancerNew England Journal of Medicine, 2008